



Updated Monthly

January 9, 2024

THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:





Questions?

Liz Powell, Esq., MPH

lpowell@G2Gconsulting.com

www.G2Gconsulting.com

  @G2Gconsulting





GBG Report

Updated Monthly

January 9, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

TABLE OF CONTENTS

New Opportunities

Advanced Research Projects Agency for Health	2
Agriculture.....	2
Amyotrophic Lateral Sclerosis	3
Biomedical Research.....	3
Biotechnology and Biomanufacturing.....	3
Cancer	4
Central Nervous System	5
Cognitive and Brain Health.....	6
Communication Disorders.....	7
Complementary and Integrative Health.....	7
Coronavirus	7
Diagnostics.....	8
Endocrine and Metabolic Disease.....	8
Energy Science	9
Genomics.....	9
HIV/AIDS	10
Immunology & Infectious Disease	11
Maternal and Pediatric Health	11
Medical Countermeasures.....	12
Mental Health.....	12
Military Prototype Advancement Initiative.....	13

Patient-Centered Research	13
Radiation Exposure.....	15
Rare Diseases	15
Reference Materials.....	15
Research Support	15
Sleep Health	16
Small Business Development	16
Substance Use Disorder	17
Therapeutics.....	18
Women's Health.....	19

Recurring Opportunities

Advanced Research Projects Agency for Health	20
Air Force	20
Army.....	21
BARDA	22
DARPA	23
Defense Threat Reduction Agency	23
Department of Energy.....	24
National Science Foundation	24
Navy	24

GBG Acronyms	25
--------------------	----



January 18, 2024 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EST (FREE to all) and 12:30-1:00pm EST (premium service private consultation for G2G and GBG clients). If you’re an affiliate of BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Health Industry Forum, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, or VaBio – your membership gets you access to the private consultation webinar.

MHSRS News: The [MHSRS abstract submission window](#) is now open! Abstracts are due by February 21, with the conference to be held in August. On **February 14**, G2G is hosting a webinar with tips on submitting to MHSRS and will also share info about the SOMA conference in May. Watch your email for details!

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (1)		
1.	Presolicitation: Research and development (R&D) that will contribute toward Advanced Research Projects Agency for Health (ARPA-H) mission needs and Small Business Innovation Research (SBIR) program objectives. (ARPA-H) 75N91024R00006	ARPA-H will solicit proposals that possess the R&D expertise to conduct innovative research in the following research topics: ARPA-H 01 - Inexpensive plant-based manufacturing of viruses; ARPA-H 02 - LymphoLab ProDiscover Kit; ARPA-H 03 - Continuous Monitoring of Vascular health using Smart Biomimetic Implantables; ARPA-H 04 - Personalized medicine platform for predicting response to immunotherapy; ARPA-H 05 - Saving Baby Hearts: Fully Autonomous Neonatal Echocardiography for the Diagnosis of Critical Congenital Heart Disease; ARPA-H 06 - Improving Identity and Access Management with Clinical Context. https://sam.gov/opp/ccoe634201084b2b8f20e5ba59ee59a5/view	TBD	Estimated post date: 1/23/24 Estimated proposal date: 2/22/24
		AGRICULTURE (1)		
2.	Agriculture and Food Research Initiative Competitive Grants Program Foundational and Applied Science Program (USDA/NIFA) USDA-NIFA-AFRI-010453	The AFRI Foundational and Applied Science Program supports grants in six AFRI priority areas to advance knowledge in both fundamental and applied sciences important to agriculture. The six priority areas are: Plant Health and Production & Plant Products; Animal Health and Production and Animal Products; Food Safety, Nutrition, and Health; Bioenergy, Natural Resources, and Environment; Agriculture Systems and Technology; and Agriculture Economics and Rural Communities. https://www.nifa.usda.gov/grants/funding-opportunities/agriculture-food-research-initiative-foundational-applied-science	Up to \$15 million Dependent upon proposal and award mechanism	Letter of intent: 12/31/24 Proposal: Varies by program area



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AMYOTROPHIC LATERAL SCLEROSIS (4)		
3.	Pre-Announcement: FY24 Amyotrophic Lateral Sclerosis Research Program (DoD/CDMRP)	Four awards are anticipated in the ALSRP: Pilot Clinical Trial Award; Clinical Outcomes and Biomarkers Award; Therapeutic Development Award; and Therapeutic Idea Award. FY24 ALSRP Pilot Clinical Trial Award applications must address one of the following Focus Areas: Interventions and Clinical Care. FY24 ALSRP Clinical Outcomes and Biomarkers Award applications must address one or both Focus Areas: Clinical Biomarkers and Clinical Outcomes. https://cdmrp.health.mil/pubs/press/2024/24alsrppreann	Up to \$2 million, for up to 4 years Dependent upon award mechanism	TBD
		BIOMEDICAL RESEARCH (1)		
4.	NOSI: Quantum Sensing Technologies in Biomedical Applications (NIH) NOT-EB-23-022	The goal of this NOSI is to support innovative and potentially transformative research projects in quantum science and sensing toward biomedical disciplines. This includes approaches to improve current biomedical imaging and bioengineering tools and technologies using quantum sensing for drug delivery, novel therapeutics, detection, diagnosis, treatment, and monitoring of various diseases. https://grants.nih.gov/grants/guide/notice-files/NOT-EB-23-022.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/27/27
		BIOTECHNOLOGY AND BIOMANUFACTURING (5)		
5.	Bioimaging Research Approaches for the Bioeconomy & the Environment (DoE) DE-FOA-0003231	BER is soliciting applications in the following subtopic areas: 1) fundamental imaging or sensing research from concept to validation or 2) evaluation of biological hypotheses or questions with feasible, use-inspired prototypes. Under subtopic 1) applications could evaluate, untested concepts, and theoretical models, develop novel experimental prototypes and validate measurement accuracy against known technical or biological validation standards. Under subtopic 2) research of experimental prototypes of instruments and methods that will include demonstration of feasibility leading to hypothesis-driven biological experimentation to demonstrate value to the user community. https://www.grants.gov/search-results-detail/351379	Up to \$2.35 million	Pre-Application: 1/9/24 Proposal: 3/5/24
6.	DCL: Funding Opportunities for Engineering Research in Biotechnology (NSF) NSF 24-040	The NSF encourages the submission of research and education proposals related to Biotechnology as an Emerging Industry. Advances supported by NSF and the Engineering Directorate include genome sequencing, editing, and synthesis; synthetic and engineered biology; imaging and biosensing; and tissue engineering and biomanufacturing. https://new.nsf.gov/funding/opportunities/funding-opportunities-engineering-research-0	Dependent upon proposal and award mechanism	Proposal: 4/30/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOTECHNOLOGY AND BIOMANUFACTURING		
7.	DCL: Funding Opportunities for Engineering Research in Emerging Areas of Advanced Manufacturing (NSF) NSF 24-043	Research in emerging areas of Advanced Manufacturing will accelerate breakthroughs in manufacturing materials, technologies, and systems through fundamental, multidisciplinary research that transforms manufacturing capabilities, methods, and practices. NSF and Engineering Directorate investments will spur manufacturing breakthroughs in advanced energy- and resource-efficient industrial technologies, resilient manufacturing strategies, novel methods in engineering biology, next-generation materials, and the power of data science, automation, robotics, and machine learning to intelligently design and develop future approaches that are secure, sustainable, and resilient to natural and anthropogenic disasters. https://www.nsf.gov/pubs/2024/nsf24043/nsf24043.jsp	Dependent upon program and available funding	Proposal: 4/30/24
8.	ARPA-H Resilient Extended Automatic Cell Therapies (REACT) (ARPA-H) ARPA-H-MAI-24-01-02	REACT aims to overcome the problems surrounding medication non-adherence by creating two different—but related—bioelectronic devices capable of treating chronic conditions remotely. These devices will be implanted in patients during minor outpatient surgery and will interface with a simple software platform or app that allows users to track their condition directly. https://sam.gov/opp/0625eee72aa34ac1a256dd28878b5711/view	Dependent upon proposal and award mechanism	Proposal: 1/26/24
9.	Responsible Design, Development, and Deployment of Technologies (ReDDDoT) (NSF) NSF 24-524	In FY 2024, the Planning Grant, Translational Research Coordination Network, and Phase 2 Project proposals should all focus on one or more of the following three technology areas, selected as priority areas from the list of technology areas enumerated in the CHIPS & Science Act: artificial intelligence, biotechnology, or natural and anthropogenic disaster prevention or mitigation. https://new.nsf.gov/funding/opportunities/responsible-design-development-deployment	Up to \$1.5 million, for up to 3 years Dependent upon award mechanism	Proposal: 4/8/24 (Phase 1) Proposal: 4/22/24 (Phase 2)
		CANCER (14)		
10.	Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) (NIH Common Fund) PAR-24-082	The NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First Program supported sequencing centers. Applicants are encouraged to propose sequencing of existing pediatric cancer or structural birth defect cohorts to elucidate the genetic contribution to childhood cancers, to investigate the genetic etiology of structural birth defects, to study the molecular basis of the associations between birth defects and increased cancer risk, or to expand the range of pediatric disorders included within the Kids First Data Resource. https://grants.nih.gov/grants/guide/pa-files/PAR-24-082.html	N/A	Letter of intent: 2/13/24 Proposal: 3/13/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
11.	Informatics Technologies for Cancer Research and Management (R21/U01/U24 Clinical Trial Optional) (NIH/NCI) RFA-CA-24-016 (R21) RFA-CA-24-017 (U01) RFA-CA-24-018 (U24) RFA-CA-24-019 (U24)	These FOAs invite applications for the development, enhancement, and sustainment of informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-014.html (R21) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-015.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-016.html (U24) https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-017.html (U24)	Up to \$275,000, for up to 2 years (R21) Up to \$300,000 per year, for up to 3 years (U01) Dependent upon proposal, for up to 5 years (U24)	Letter of intent: 5/11/24 Proposal: 6/11/24
12.	Cancer Prevention and Control Clinical Trials Grant Program and Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) (NIH/NCI) PAR-24-072 (R01) PAR-24-085 (R01)	NCI invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; and solicits research projects that implement early phase investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-24-085.html (R01)	Dependent upon proposal, for up to 5 years (R01) Up to \$499,999 per year, for up to 5 years (R01)	Letter of intent: 5/5/24 Proposal: 6/5/24
13.	Pre-Announcement: FY24 Ovarian Cancer Research Program (DoD/CDMRP)	The OCRP will support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service Members, Veterans, their Family members, and all women impacted by this disease. Seven awards are anticipated: Clinical Trial, Clinical Trial Translational Endpoints, Investigator-Initiated Research, Ovarian Cancer Academy - Leadership, Ovarian Cancer Academy - Early-Career Investigator, Ovarian Cancer Clinical Trial Academy - Early-Career Investigator, and Pilot Award. https://cdmrp.health.mil/pubs/press/2024/24ocrppreann	Up to \$2 million, for up to 4 years Dependent upon award mechanism	TBD
		CENTRAL NERVOUS SYSTEM (2)		
14.	Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed) (NIH) PAR-24-088	This NOFO will support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds. https://grants.nih.gov/grants/guide/pa-files/PAR-24-088.html	Dependent upon proposal, for up to 5 years	Proposal: 2/5/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CENTRAL NERVOUS SYSTEM		
15.	NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional) (NIH/NINDS) PAR-24-101	This NOFO encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. https://grants.nih.gov/grants/guide/pa-files/PAR-24-101.html	Dependent upon proposal, for up to 5 years	Proposal: 3/19/24
		COGNITIVE AND BRAIN HEALTH (27)		
16.	Collaborative Research in Computational Neuroscience (CRCNS) (NSF) NSF 24-510	Two classes of proposals will be considered: Research Proposals should describe innovative, collaborative projects focused on challenging interdisciplinary problems in computational neuroscience. Data Sharing Proposals should focus on the preparation and deployment of data, software, code bases, stimuli, models, or other resources in a manner that will enable wide-ranging research advances in computational neuroscience. https://www.nsf.gov/pubs/2024/nsf24510/nsf24510.htm	Dependent upon proposal and available funding	Proposal: 3/7/24
17.	NOSI: Neuromodulatory Control of Circuits Underlying Mental Health Relevant Behaviors (NIH/NIMH) NOT-MH-24-100	This NOSI solicits applications seeking to understand how neuromodulatory signals dynamically control and coordinate neural circuit responses in real-time during complex mental health relevant behaviors including cognitive, social, and affective functions. These studies are expected to utilize recent tools that enable precise assessment of spatiotemporal dynamics of extracellular release or receptor activation of neuromodulators with simultaneous causal interrogation of neural activity and behavioral responses. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-24-100.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/10/27
18.	NOSI: Fundamental Mechanisms and Functions of Co-transmission in the Brain (NIH/NIMH/NIAAA/NIDA) NOT-MH-24-105	This NOSI encourages basic neuroscience research in animals to investigate the fundamental mechanisms and functions of co-transmission that support brain activity and behavior. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-24-105.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 2/4/27
19.	Pre-Announcement: FY24 Peer Reviewed Alzheimer's Research Program (DoD/CDMRP)	Three awards are anticipated in the PRARP: Transforming Care Award; Transforming Diagnosis Award; and Transforming Research Award. All FY24 PRARP mechanisms have a Career Initiation or Transition Partnering PI Option (CITPO) to encourage research capacity in this critical area. https://cdmrp.health.mil/pubs/press/2024/24prarppreann	Up to \$2 million, for up to 4 years Dependent upon award mechanism	TBD



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
20.	NOSI: Translation of BRAIN Initiative Technologies to the Marketplace (NIH) NOT-MH-24-115	This NOSI alerts SBCs and partnering institutions that there is a need to help move useful BRAIN Initiative-developed technologies and BRAIN Initiative-relevant technologies from non-commercial laboratories into the commercial marketplace. Supported research and development will include further development, optimization, validation and scaling of technologies for commercial dissemination. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-24-115.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 4/5/27
		COMMUNICATION DISORDERS (1)		
21.	NIDCD Research Opportunities for New Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional) (NIH/NIDCD) RFA-DC-24-007	This NOFO solicits applications that propose independent research projects that are within the scientific mission areas of the NIDCD. This program is intended to support Early Stage and New Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-24-007.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 1/28/24 Proposal: 2/28/24
		COMPLEMENTARY AND INTEGRATIVE HEALTH (5)		
22.	NCCIH Multi-Site, Feasibility, Investigator Initiated Clinical Trials of Mind and Body Interventions; Data and Clinical Coordinating Centers (R01/R34/U24/UG3/UH3 Clinical Trial Required) (NIH/NCCIH) PAR-24-083 (R01) PAR-24-084 (R34) PAR-24-086 (R01) PAR-24-087 (U24) PAR-24-090 (UG3/UH3)	These NOFOs support investigator-initiated clinical trials, feasibility trials, remotely delivered clinical trials; and a collaborating Data Coordinating Center and Clinical Coordinating Centers. Research should address complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. https://grants.nih.gov/grants/guide/pa-files/PAR-24-083.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-24-084.html (R34) https://grants.nih.gov/grants/guide/pa-files/PAR-24-086.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-24-087.html (U24) https://grants.nih.gov/grants/guide/pa-files/PAR-24-090.html (UG3/UH3)	Dependent upon proposal, for up to 5 years (R01/U24/UG3/UH3) Up to \$450,000, for up to 3 years (R34)	Proposal: 2/20/24 (R01/R34/R01) Proposal: 6/20/24 (U24/UG3/UH3)
		CORONAVIRUS (1)		
23.	NOSI: The Impact of Post-Acute Sequelae of SARS-CoV-2 Infection on Mission Specific Sensory and Communication Disorders (NIH/NIDCD) NOT-DC-24-001	NIDCD invites applications for research on PASC in relation to NIDCD's scientific programs of hearing, balance, taste, smell, voice, speech and language. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models. https://grants.nih.gov/grants/guide/notice-files/NOT-DC-24-001.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/30/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DIAGNOSTICS (1)		
24.	JPMO CBRN Medical seeks to develop an FDA cleared diagnostic assay able to differentiate between bacterial and viral infection in human clinical samples (DoD/Army) W911SR-24-R-ADD1	This program seeks to provide a toolkit of materiel solutions that will focus on early medical intervention across the deployed medical community for Roles of Care (ROC) 1, 2, and 3. The initial capability that will be delivered by the program is a Bacterial vs Viral (B vs. V) diagnostic solution. The B vs. V capability is envisioned as an in vitro diagnostic assay utilizing measurable host-response analytes from clinically appropriate biological samples to support early patient treatment decisions. https://sam.gov/opp/311c5baa658d4b8d9d48c93499e98ae0/view	Dependent upon proposal and award mechanism	Proposal: 1/15/24
		ENDOCRINE AND METABOLIC DISEASE (5)		
25.	NIDDK High Risk Multi-Center Clinical Study Implementation Planning and Clinical Study Cooperative Agreements (U34 CT Optional/U01 CT Not Allowed/U01 CT Required) (NIH/NIDDK) PAR-24-094 (U34) PAR-24-102 (U01) PAR-24-103 (U01)	These NOFO invite applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center; also planning activities. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. https://grants.nih.gov/grants/guide/pa-files/PAR-24-094.html (U34) https://grants.nih.gov/grants/guide/pa-files/PAR-24-102.html (U01) https://grants.nih.gov/grants/guide/pa-files/PAR-24-103.html (U01)	Up to \$225,000 per year, for up to 2 years (U34) Dependent upon proposal, for up to 5 years (U01)	Letter of intent: 9/9/24 Proposal: 10/9/24 (U34) Letter of intent: 5/5/24 Proposal: 6/5/24 (U01)
26.	Pre-Announcement: Type 1 Diabetes TrialNet Coordinating Center and Clinical Network Hub (U01 Clinical Trial Required/Not Allowed) (NIH/NIDDK) NOT-DK-24-004 (U01) NOT-DK-24-005 (U01)	The TNCC will: (1) support a wide range of research projects in varying stages of development, implementation and completion, and (2) provide data and sample management, including standardized acquisition, quality control, dissemination and public accessibility. The main objective of the HUB is to increase the efficiency and productivity of the TrialNet network by providing coordination of communications and outreach and developing new tools and approaches to increase screening, recruitment and retention. https://grants.nih.gov/grants/guide/notice-files/NOT-DK-24-004.html	Up to \$29.5 million per year, for 5 years (TNCC) Up to \$1 million per year, for 5 years (HUB)	Estimated post date: 1/26/24 Estimated proposal date: 6/14/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENERGY SCIENCE (3)		
27.	Grid-free Renewable Energy Enabling New Ways to Economical Liquids and Long-term Storage (GREENWELLS) (DoE/ARPA-E) DE-FOA-0003234 DE-FOA-0003235	The primary objective of the GREENWELLS program is the development of chemical reactors and supporting units that economically store at least 50% of incoming intermittent electrical energy in carbon-containing liquids. To achieve attractive economics, ARPA-E expects that chemical reactors will need to be dynamically operable to optimize the entire system of renewable energy production, electrolysis capital, and energy storage. Thermal, electrochemical, plasmonic, photonic, biological, and other technical process approaches are expected to potentially address this problem. https://www.grants.gov/search-results-detail/351440 https://www.grants.gov/search-results-detail/351442	Up to \$5 million Dependent upon award mechanism	Proposal: 1/25/24
28.	Pre-Announcement: Regional Resource Hubs for Purpose-Grown Energy Crops (DoE) DE-FOA-0003233	This program will fund high-impact R&D focused on mobilizing low carbon intensity, purpose-grown energy crops. The goal of the anticipated AOI will be to demonstrate the long-term yield and sustainability of purpose-grown energy crops across varied agronomic and geographic landscapes that will accelerate feedstock supply chain development through the generation of data for use by analysts, policy makers, and industry. https://eere-exchange.energy.gov/Default.aspx#FoalD997a0a96-aaac-4b8e-8c6d-494aea026cee	TBD	Estimated post date: January 2024
		GENOMICS (7)		
29.	Discovering Unknown Function (DUF) (DoD/DARPA) DARPA-EA-24-01-02	DUF performers will develop reproducible high-throughput gene function discovery workflows using recent technological advances, such as automated cultivation techniques, microfluidics, single-cell multi-omics, bioinformatics, cloud computing, whole-cell modeling, artificial intelligence, machine learning, and computational microscopy. https://sam.gov/opp/4e86ad556e184738b83ebb1coe0bf6aa/view	Up to \$300,000, for up to 1 year	Abstract: 4/5/24
30.	Trans-Omics for Precision Medicine (TOPMed) Informatics Research Center (IRC) (NIH/NHLBI) 75N92023R0194	The overarching goal of the IRC is to continue to generate capacities and new tools and methodologies for managing, processing, analyzing, harmonizing and sharing the continuously increasing volume of whole genome sequencing (WGS) data, multi-omics data, and other data sources to advance and improve HBSL basic, translational, and clinical research and treatments. https://www.fedconnect.net/FedConnect/default.aspx?ReturnUrl=%2fFedConnect%2f%3fdoc%3d75N92023R0194%26agency%3dHHS-NIH&doc=75N92023R0194&agency=HHS-NIH	Up to \$30 million, for up to 5 years	Proposal: 2/9/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		GENOMICS		
31.	NOSI: Advancing Genomic Technology Development for Research and Clinical Application (NIH/NHGRI) NOT-HG-24-012	This NOSI encourages applications focused on developing novel laboratory-focused tools and technologies that enable new lines of scientific inquiry and advance research or clinical applications in human genomics. https://grants.nih.gov/grants/guide/notice-files/NOT-HG-24-012.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/10/27
32.	NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed) (NIH/NHGRI) RFA-HG-24-006	The Center's activities will include facilitating opportunities for new research collaborations to advance technology development and dissemination. The Center will also develop outreach strategies and resources to engage the broader biomedical research community and provide an Opportunity Funds Program to support innovative small-scale work. https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-24-006.html	Dependent upon proposal, for up to 5 years	Letter of intent: 3/1/24 Proposal: 4/2/24
		HIV/AIDS (4)		
33.	Multidisciplinary Studies of HIV/AIDS and Aging (R01/R21 Clinical Trial Optional) (NIH) PAR-24-091 (R01) PAR-24-092 (R21)	These NOFOs invite applications at the intersection of HIV and aging by proposing research that aims to meet the following objectives: 1) Improve the understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) Improve approaches for testing, preventing, and treating HIV infection, and managing HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying current aging science approaches. https://grants.nih.gov/grants/guide/pa-files/PAR-24-091.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-24-092.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Proposal: 6/5/24 (R01) Proposal: 6/16/24 (R21)
34.	Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R01/R21 Clinical Trial Not Allowed) (NIH/NIDA) RFA-DA-25-007 (R01) RFA-DA-25-008 (R21)	These NOFOs support research on (1) the development of novel tools, methods, and molecular probes to identify mechanisms and signaling pathways by which addictive substances influence HIV latency and transcriptional reactivation in the central nervous system (CNS), and (2) identification and functional validation of novel lead compounds that suppress HIV transcription in the context of addictive substances. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-007.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-008.html (R21)	Up to \$400,000 per year, for up to 5 years (R01) Up to \$275,000, for up to 2 years (R21)	Letter of intent: 7/13/21 Proposal: 8/13/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE (4)		
35.	Bat Immunology Network Research Projects and Resource Program (R01/U24 CT Not Allowed) (NIH/NIAID) RFA-AI-23-068 (R01) RFA-AI-23-069 (U24)	These NOFOs support research to characterize cellular and molecular constituents of the bat immune system and to understand protective innate and adaptive immune mechanisms in bats; and the development and validation of reagents/tools to support this research. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-068.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-069.html (U24)	Up to \$300,000 per year, for up to 5 years (R01) Up to \$350,000 per year for 5 years (U24)	Letter of intent: 4/24/24 Proposal: 5/24/24
36.	Epidemiology and Prevention of Infection and Related Diseases (NIH/NCI) 75N91024R00005	The objective is to build a comprehensive body of evidence evaluating HPV vaccine protection for adolescents and adults with the ultimate goal to make huge advances towards controlling cervical cancer globally in the next decade. Secondary goals are to study the epidemiology and prevention of infections and related diseases of public health importance using the infrastructure and methodology developed within the HPV vaccination framework. https://sam.gov/opp/80e0aa7bfe034b0790d556f9f33e90b2/view	Up to \$49 million, for 10 years	Proposal: 2/27/24
37.	Research Initiative for Vaccine and Antibiotic Allergy (UG3/UH3 CT Not Allowed) (NIH/NIAID) RFA-AI-24-002	The objective of this NOFO is to solicit innovative projects to study the mechanisms and management of vaccine or antibiotic drug allergy (research on allergic responses to anti-viral, anti-fungal and anti-parasitic drugs will also be considered). https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-002.html	Up to \$250,000 per year, for up to 5 years	Letter of intent: 5/21/24 Proposal: 6/21/24
		MATERNAL AND PEDIATRIC HEALTH (3)		
38.	Maternal Morbidity and Mortality Topical PCORI Funding Announcement – Cycle 1 2024 (PCORI)	This PFA seeks to fund high-quality, patient-centered comparative clinical effectiveness research (CER) projects that focus on maternal morbidity and mortality (MMM). Primary outcomes of interest may include MMM; SMM; condition-specific outcomes; healthcare utilization, including readmission and emergency department visits; labor characteristics. https://www.pcori.org/funding-opportunities/announcement/maternal-morbidity-and-mortality-topical-pcori-funding-announcement-cycle-1-2024	Up to \$12 million, for up to 5 years	Letter of intent: 2/6/24 Proposal: 5/7/24
39.	Pre-Announcement: Clinical Sites and Data Coordinating Center for ECHO IDeA States Pediatric Clinical Trials Network - 3 (UG1 CT Required/U24 CT Optional Infrastructure) (NIH) NOT-OD-24-045 (UG1) NOT-OD-24-046 (U24)	Each ISPCTN Clinical Site will support site readiness to participate in approximately five ECHO ISPCTN multicenter pediatric clinical trials related to prevention or treatment of one or more of ECHO's five outcome areas of interest: pre-, peri-, and postnatal outcomes; upper and lower airways; obesity; neurodevelopment; and positive health. The DCOC award budget will fund the associated clinical trials. Organizations must be located in IDeA states. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-045.html (UG1) https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-046.html (U24)	Up to \$300,000 (UG1) \$1.75 million per year, for infrastructure; \$3.5 million to distribute (U24)	Estimated post date: 1/15/24 Estimated proposal date: 4/15/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MEDICAL COUNTERMEASURES (4)		
40.	2024 NIAID Omnibus Broad Agency Announcement: "Development of Medical Countermeasures for Biodefense and Emerging Infectious Diseases" (NIH/NIAID) HHS-NIH-NIAID-BAA-2024-1	NIAID supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. This BAA solicits proposals proposing research into one of three areas: Vaccine Candidates; Therapeutic Candidates; and In Vitro Diagnostics. https://sam.gov/opp/82db2ed766f84d8bbbed9064493c3bbe3/view	Dependent upon proposal and award mechanism	Proposal: 3/12/24
41.	Centers of Excellence for Translational Research (CETR) (U19 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-23-065	This program will support multidisciplinary translational research Centers focused on generating, validating, and advancing medical countermeasures against bacteria or fungi listed in the NOFO with known and emerging resistance to current therapies. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-065.html	Up to \$5 million per year, for up to 5 years	Letter of intent: 3/29/24 Proposal: 4/29/24
42.	NIAID/NIH Centers for Medical Countermeasures Against Radiation (CMCR) Program Call for Pilot Project Applications 2024 (NIH/NIAID/CMCRC)	Pilot project funding is intended to: Foster novel/early ideas within and outside awarded CMCRs; Develop or incorporate new technologies as they become available; Encourage collaborations among members of different centers and between the CMCR and outside investigators; Allow maximum flexibility for the advancement of exciting high-risk, high-reward projects. https://cmcrniaid.org/content/instructions	Up to \$100,000 per year, for up to 1 year	Proposal: 3/1/24
43.	RFI: BARDA's RRPV - On-Demand Manufacturing (HHS/BARDA) RFI-24-02-ODM	BARDA is interested in learning more about On-Demand Manufacturing that will enable rapid response, smaller-scale production of pharmaceutical medical counter measures closer to their areas of immediate need. https://www.rpv.org/solicitation/rfi-on-demand-manufacturing/	N/A	Industry day: 1/16/24 Response: 1/19/24
		MENTAL HEALTH (1)		
44.	NOSI: Behavioral Tasks Targeting Brain Systems Relevant to Anhedonia (NIH/NIMH) NOT-MH-24-130	This NOSI supports research on task-based behavioral measures that engage brain systems relevant to anhedonia. The goal is to identify a battery of behavioral tasks that can be used as quantitative tools for future use in the evaluation of dysfunction within domains of mental health relevant to anhedonia and for future treatment development. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-24-130.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOSI open through 1/7/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MILITARY PROTOTYPE ADVANCEMENT INITIATIVE (1)		
45.	Military Prototype Advancement Initiative (MPAI) (MTEC) MTEC-24-01-MPAI	This RPP solicits a broad range of medical prototype technological and knowledge solutions related to the Focus Areas of Interest listed below. Proposed solutions may include medical techniques, knowledge products, and materiel. The focus areas are: Combat Casualty Care, Military Infectious Diseases, Military Operational Medicine, and USAF School of Aerospace Medicine. Topics include Precision Medicine, Carcinogens, Wound Management/Burn Healing, Vaccines, and Infection Prevention. https://mtec-sc.org/wp-content/uploads/2023/10/MTEC-24-01-MPAI-RPP.pdf	Dependent upon proposal	Proposal: 1/22/24
		PATIENT-CENTERED RESEARCH (7)		
46.	Advancing the Science of Engagement PCORI Funding Announcement -- Cycle 1 2024 (PCORI)	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes; Techniques that lead to effective engagement; How these techniques should be modified and resourced for different contexts, settings, and communities to ensure equity; How engagement supports successful research. https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-pcori-funding-announcement-cycle-1-2024	Up to \$1.5 million, for up to 3 years	Letter of intent: 2/6/24 Proposal: 5/7/24
47.	Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research -- 2024 Standing PFA (Cycle 1 2024) (PCORI)	For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in Clinical Research; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-2024-standing-pfa-cycle-1-2024	Up to \$750,000, for up to 3 years	Letter of intent: 2/6/24 Proposal: 5/7/24
48.	Open Competition PFA: Implementation of Findings from PCORI's Major Research Investments -- Cycle 1 2024 (PCORI)	For this PFA, PCORI has identified the following four areas of eligible evidence: Obesity Treatment in Primary Care Settings; Nonsurgical treatment options can improve or eliminate symptoms for women with urinary incontinence (UI); Several kinds of therapy and medicines can reduce or stop symptoms for people with PTSD; The use of narrow-spectrum versus broad-spectrum antibiotics to treat children's acute respiratory tract infections (ARTIs). https://www.pcori.org/funding-opportunities/announcement/open-competition-pcori-funding-announcement-implementation-findings-pcoris-research-investments-cycle-1-2024	Up to \$2.5 million, for up to 4 years	Letter of intent: 2/6/24 Proposal: 5/7/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH		
49.	Implementation of Effective Shared Decision Making Approaches in Practice Settings -- Cycle 1 2024 (PCORI)	<p>This initiative will support projects that propose active, multi-component approaches to implementing effective shared decision making strategies that address existing barriers and obstacles to uptake and maintenance, so that these interventions are effectively and sustainably integrated into practice. The SDM strategy must have demonstrated effectiveness on patient, caregiver, or healthcare provider decision making using widely accepted metrics; the corresponding implementation approach must have potential for use and scalability beyond the targeted implementation setting.</p> <p>https://www.pcori.org/funding-opportunities/announcement/implementation-effective-shared-decision-making-approaches-practice-settings-cycle-1-2024</p>	Up to \$2.5 million, for up to 4 years	Letter of intent: 2/6/24 Proposal: 5/7/24
50.	Phased Large Awards for Comparative Effectiveness Research (PLACER) -- Cycle 1 2024 (PCORI)	<p>This PFA invites applications for high-quality comparative clinical effectiveness research (CER) projects that will address critical decisions faced by patients, caregivers, clinicians, and stakeholders across the health and healthcare community and for which there is insufficient evidence. Applications must address at least one of the National Priorities for Health.</p> <p>https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-placer-cycle-1-2024</p>	Up to \$22 million, for up to 6.5 years	Letter of intent: 2/6/24 Proposal: 5/7/24
51.	Broad Pragmatic Studies Funding Announcement -- 2024 Standing PFA (Cycle 1 2024) (PCORI)	<p>This PFA invites applications for high-quality comparative clinical effectiveness research projects. All applications must align the proposed research with at least one of the National Priorities for Health. Applicants have the option to choose up to three of twelve topic themes, based on how their proposed research aligns with the themes.</p> <p>https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-funding-announcement-2024-standing-pfa-cycle-1-2024</p>	Up to \$12 million, for up to 5 years Dependent upon award mechanism	Letter of intent: 2/6/24 Proposal: 5/7/24
52.	Intellectual and Developmental Disabilities Topical PCORI Funding Announcement -- Cycle 1 2024 (PCORI)	<p>This PFA seeks to fund high-quality, patient-centered comparative clinical effectiveness research (CER) projects that focus on people with intellectual and developmental disabilities (IDD). Three Special Areas of Emphasis are: Promoting Sleep Health, Improving Health and Quality of Life in Down Syndrome, Improving Care Delivery.</p> <p>https://www.pcori.org/funding-opportunities/announcement/intellectual-and-developmental-disabilities-topical-pcori-funding-announcement-cycle-1-2024</p>	Up to \$12 million, for up to 5 years	Letter of intent: 2/6/24 Proposal: 5/7/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		RADIATION EXPOSURE (1)		
53.	Integrated Biological and Computational Low-Dose Radiation Research (DoE) DE-FOA-0003281	The long-term goal is to build on the understanding of radiation effects on cellular function and establish comprehensive datasets amenable to incorporation into increasingly capable AI/ML models to identify both transient and persistent changes in cellular metabolism that may be linked to adverse health outcomes. https://science.osti.gov/ber/-/media/grants/pdf/foas/2024/DE-FOA-0003281.pdf	Up to \$500,000 per year, for up to 3 years	Pre-Application: 2/6/24 Proposal: 4/2/24
		RARE DISEASES (1)		
54.	Natural History, Clinical Outcome Assessment, and Biomarker Studies of Rare Neurodegenerative Diseases (U01) Clinical Trials Optional (FDA/OC/OOPD) RFA-FD-24-024	This FOA supports efficient natural history studies alone or in conjunction with the development and validation of clinical outcome assessments (COAs) and/or biomarker studies to address the unmet needs in rare neurodegenerative diseases for children and adults. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-024.html	Dependent upon proposal, for up to 4 years	Letter of intent: 4/6/24 Proposal: 5/6/24
		REFERENCE MATERIALS (1)		
55.	Accreditation of CBER's Laboratory Quality System and Reference Materials Production (FDA/CBER) 75F40124R00024	The objective of this contract is to renew accreditation of CBER's pharmaceutical testing and reference material production activities to international standard ISO 17025 "General requirements for the competence of testing and calibration laboratories" and ISO 17034 "General requirements for the competence of reference material producers". After accreditation is granted, an alternating schedule of biennial on-site assessments and alternating year document reviews is required. https://sam.gov/opp/d9fdecce1c3c4a0697eae57aabc76d46/view	Dependent upon contract	Proposal: 1/15/24
		RESEARCH SUPPORT (2)		
56.	Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed/R01 Basic Experimental Studies with Human Required) (NIH) PAR-24-075 (R01) PAR-24-076 (R01)	These NOFOs support innovative projects that represents a change in research direction for an ESI and for which no preliminary data exist. Types of studies that should submit under this NOFO include studies that prospectively assign human participants to conditions and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. https://grants.nih.gov/grants/guide/pa-files/PAR-24-075.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-24-076.html (R01)	Dependent upon proposal, for up to 5 years	Proposal: 1/26/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SLEEP HEALTH (1)		
57.	Sleep Health Topical PCORI Funding Announcement -- Cycle 1 2024 (PCORI)	This PFA will fund high-quality, comparative clinical effectiveness research (CER) projects that focus on sleep health. PCORI is particularly interested in applications focusing on sleep in high-need and/or underserved populations https://www.pcori.org/funding-opportunities/announcement/sleep-health-topical-pcori-funding-announcement-cycle-1-2024	Up to \$12 million, for up to 5 years	Letter of intent: 2/6/24 Proposal: 5/7/24
		SMALL BUSINESS DEVELOPMENT (4)		
58.	Navy SBIR 24.1 - Phase I and Direct to Phase II (DoD/Navy) 24.1 SBIR	Topics include: Medical Echelon of Care Conceptual Models for Wargaming, Safeguarding Warfighter Medical Data: Secure Encrypted Transmission of Physiologic Monitoring (PhysMon) Data https://www.defensesbirsttr.mil/SBIR-STTR/Opportunities/	Up to \$240,000, for one year (Phase I) Up to \$1.3 million for up to 3.5 years (Phase II)	Proposal: 2/7/24
59.	DHA SBIR 24.1 - Phase I & Direct to Phase II (DoD/DHA) 24.1 SBIR	Topics include: Psoralen-UV-A Irradiation Based High-throughput Pathogen Inactivation Device; Development of a Junctional Tourniquet; Rapid Manufacturing of Personalized Braces and Splints for Musculoskeletal Injury; Wireless, Wearable Personal Metabolic Sensor. https://www.defensesbirsttr.mil/SBIR-STTR/Opportunities/	Up to \$250,000, for up to 6 months (Phase I) Up to \$1.3 million for up to 2 years (Phase II)	Proposal: 2/7/24
60.	SOCOM SBIR 24.4 Phase I (DoD/SOCOM) 24.4 SBIR	The capability to provide water tester at point-of-need will incorporate a durable and small-scale piece of equipment that is able to withstand travel and ground movement while simultaneously providing rapid results on microbiological health threats and metal exposures. https://www.defensesbirsttr.mil/SBIR-STTR/Opportunities/	Up to \$175,000, for 7 months	Proposal: 2/6/24
61.	DoD 24.4 SBIR Annual BAA Release 5 (DoD/Army) 24.4 SBIR	The goal of this effort is the development of a medical multi-mission, modular payload that can be employed by robotic ground and air platforms. https://www.defensesbirsttr.mil/SBIR-STTR/Opportunities/	Up to \$1.65 million, for up to 1 year	Proposal: 1/30/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER (4)		
62.	Development of Clinical Outcome Assessments as New FDA-Qualified Drug Development Tools to Accelerate Therapeutics Development for Opioid and Stimulant Use Disorders (UG3/UH3 Clinical Trial Optional) (NIH/NIDA) RFA-DA-25-028	This NOFO supports the development of Clinical Outcome Assessments (COA) for SUD. The COA development plan is expected to progress into the FDA drug development tool qualification program. Applications should contain a COA development plan that will cover both UG3 and UH3 phases. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-028.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 6/9/24 Proposal: 7/9/24
63.	High-Throughput Screening (HTS) Platform for Discovery of Medications to Treat Alcohol Use Disorder (R43/R44/R41/R42 Clinical Trials Not Allowed) (NIH/NIAAA) RFA-AA-24-001 (R43/R44) RFA-AA-24-002 (R41/R42)	These NOFOs support SBIR and STTR applications in the development of a new, or optimization of an existing, in vivo and/or in vitro high-throughput screening (HTS) platform for use in identifying potential compounds for treating AUD. Potential screening platform assays will consist of small vertebrate and invertebrate model organisms and human cell- and tissue-based models. https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-24-001.html (R43/R44) https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-24-002.html (R41/R42)	Up to \$250,000, for up to 6 months (Phase I) Up to \$1 million per year, for up to 2 years (Phase II) (R43/R44) Up to \$500,000 per year, for up to 1 year (Phase I) Up to \$1 million per year, for up to 2 years (Phase II) (R41/R42)	Proposal: 4/9/24
64.	Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional) (NIH/NIDA/NIAAA) PAR-24-060	This NOFO encourages theoretically driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. https://grants.nih.gov/grants/guide/pa-files/PAR-24-060.html	Up to \$450,000, for up to 3 years	Proposal: 2/16/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		THERAPEUTICS (5)		
65.	Cooperative Agreement to Support a Human Abuse Potential Study of Botanical Kratom (U01 Clinical Trial Required) (FDA/CDER) RFA-FD-24-025	FDA seeks applications to develop, implement, and evaluate a human abuse potential (HAP) study of botanical Kratom. Kratom alkaloids have demonstrated both affinity and activity at receptor sites known to be associated with abuse, such as mu opioid receptors. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-025.html	Up to \$3 million per year, for up to 3 years	Letter of intent: 2/2/24 Proposal: 3/4/24
66.	Collaborations to Enhance Drug Development and Regulatory Science - Clinical Trials Optional (FDA/CDER) RFA-FD-24-029	FDA and grantees will work together to develop innovative, collaborative projects in research, education, and outreach. These projects can help foster drug product innovation to 1) support efforts to accelerate drug product development; 2) support approaches to advanced manufacturing; 3) facilitate translation of basic science discoveries into therapeutics; and 4) facilitate approaches to enhance the safety, efficacy, quality, and performance of drug products. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-029.html	Up to \$5 million per year, for up to 5 years	Letter of intent: 2/5/24 Proposal: 3/4/24
67.	Biological Therapeutics Product Development Subject Matter Expert Consulting Services to Support the Development of Cell and Gene Therapy Products (NIH/NINDS) 75N95024Q00081	The NINDS has a need for biological therapeutics development subject matter expert (SME) consultants to provide technical recommendations and advice that will support the translational development of novel therapeutics (Biologics) for NIH drug discovery and development programs. The support included in this contract will cover all areas of cell and gene therapies, including chemistry, manufacturing, and controls, pharmacokinetics/pharmacodynamics, toxicology, medical writing, bioassay development, regulatory affairs, quality assurance/quality control, and biostatistics. https://sam.gov/opp/d49bd6a6cce5443c90aba5b21d605826/view	Dependent upon contract	Proposal: 1/18/24
68.	Pre-Announcement: Establishing Qualification Processes for Agile Pharmaceutical Manufacturing (EQUIP-A-Pharma) (DoD/DARPA) DARPA-PS-24-11	is soliciting innovative approaches to address challenges in qualifying drug products produced in an agile pharmaceutical manufacturing platform. EQUIP-A-Pharma will aim to develop the technology and process models to demonstrate real-time qualification of multiple drug products produced by reprogramming or reconfiguring the manufacturing platform and inform the creation of a future regulatory framework for agile pharmaceutical manufacturing. https://sam.gov/opp/4ad34752d4cc466fb9ac67e0c5c31941/view	Up to \$500,000 for 6 months (Phase 1) Up to \$11.5 million for 1 year (Phase 2) Up to \$2 million for 6 months (Phase 3)	Abstracts: 2/1/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		THERAPEUTICS		
69.	Pre-Announcement: Biologically Derived Small Molecule Regulatory Starting Materials (BioMap)	<p>ASPR IBMSC is seeking to develop a biological design-build-test cycle at population scale, beginning with an analytical/paper demonstration of production of small molecule drug substances at commercial scale. This objective will support ASPR IBMSC's broader long-term goal of developing and commercializing infrastructure that will be accessible to a broad community of users for the purpose of producing drug substances, creating a new manufacturing paradigm that can be competitive in the global market and to onshore drug production. The objective of this project is to demonstrate the ability to produce three (3) small molecule drug substances at population scale.</p> <p>https://www.biomap-consortium.org/draft-smallmolecules/</p>	TBD	TBD
		WOMEN'S HEALTH (1)		
70.	<p>NOSI: Health Influences of Gender as a Social and Structural Variable (NIH)</p> <p>NOT-OD-24-038</p>	<p>This NOSI highlights interest in receiving research and training grant applications focused on health impacts of gender-related social and structural variables.</p> <p>https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-038.html</p>	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 11/30/25





Recurring Opportunities

January 9, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (1)		
71.	Open-Office Broad Agency Announcement (BAA) 75N99223S0001	Awardees will develop groundbreaking new ways to tackle health-related challenges through high-potential, high-impact biomedical and health research. ARPA-H has identified four initial focus areas that are a priority for investment: (1) Health Science Futures; (2) Scalable Solutions; (3) Proactive Health; (4) Resilient Systems. https://sam.gov/opp/caf109b75a0449418ead3630cef1915e/view	Dependent upon proposal and award mechanism	Abstract: 3/14/24
		AIR FORCE (3)		
72.	Airman Readiness Medical Research (ARMR) Hybrid BAA FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332	Up to \$49 million, per award	White papers accepted on rolling basis until 4/30/26
73.	Research Interests of the Air Force Office of Scientific Research FA9550-23-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD). https://www.grants.gov/web/grants/view-opportunity.html?oppId=345653	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE		
74.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/web/grants/view-opportunity.html?oppld=330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		ARMY (8)		
75.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/66870bda25274773b3e5fa7cfd3coe11/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
76.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; Military Operational Medicine; Medical Biological Defense; and Medical Chemical Defense. https://www.grants.gov/web/grants/view-opportunity.html?oppld=343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
77.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	The USSOCOM Biomedical, Human Performance, and Canine Research Program aims to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; prolonged field care (PFC); human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metaanalysis; and novel post-traumatic stress, depression, and anxiety treatment. SOF medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/web/grants/view-opportunity.html?oppld=349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
78.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition. https://sam.gov/opp/e68f40ea3b224b86ab14b9d5a8af7f9c/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
79.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/e8d78dcbe9e846f2af5fd1bfd04dc27c/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
80.	Army Applications Lab BAA for Disruptive Applications W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi- domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. https://www.grants.gov/web/grants/view-opportunity.html?oppId=315517	Dependent upon proposal	Proposals accepted through 5/1/24 Pre-proposal is required
81.	Army Research Office Broad Agency Announcement Staff Research Program W911NF20S0003	The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. Research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences. https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf	Dependent upon proposal	Proposals accepted on a rolling basis until 2/19/25
82.	Army Combat Capabilities Development Command Broad Agency Announcement W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
		BARDA (2)		
83.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/opp/645772ab7baf41d7aa0a6cbbec012147/view	Dependent upon proposal	Proposal: 9/25/28



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BARDA		
84.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #15: ReDIRECT; AOI #16: Lab at Home; AOI #19: Healing Lungs; AOI #20: DRIVE Forward; AOI #25: FASTx; AOI #26: Agnostic Diagnostic. https://sam.gov/opp/79482f9236c64929938197ae21e9347a/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (2)		
85.	Biological Technologies BAA HR001123S0045	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. https://sam.gov/opp/597bf60984314db1b3ecfce393677c75/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 6/20/24
86.	Defense Sciences Office, Office-wide HR001123S0053	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Emerging Threats. https://sam.gov/opp/972be70efd7e4608b01311466edf6b0f/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 9/26/24
		DEFENSE THREAT REDUCTION AGENCY (2)		
87.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-14-24-FRCWMD-BAA	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2024
88.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): <ul style="list-style-type: none"> • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/opp/e23f86536f7840eaa868f3526a86a6ae/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEPARTMENT OF ENERGY (1)		
89.	FY 2024 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003177	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio. https://www.grants.gov/web/grants/view-opportunity.html?oppld=350408	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/24
		NATIONAL SCIENCE FOUNDATION (1)		
90.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) NSF 23-515	The NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. View project pitch details and the full list of topics . https://www.nsf.gov/pubs/2023/nsf23515/nsf23515.htm	Up to \$275,000 for up to 1 year	Project pitches accepted on a rolling basis. Submission window for invited proposals: 7/6/23 to 3/4/24
		NAVY (3)		
91.	FY23 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies N3943023S2501	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/14178e9157ad40b387ddb443071bo969/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 4/11/24
92.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001424SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.nre.navy.mil/work-with-us/funding-opportunities/fy24-long-range-broad-agency-announcement-baa-navy-and-marine	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/24
93.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-23-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/opp/ee708f6d2e244dobb59d582co362d9d1/view	Dependent upon proposal and award mechanism	White papers accepted through 3/29/24





Terms

AD/ADRD: Alzheimer's Disease / Alzheimer's Disease Related Dementias

Aoi: Area of Interest

BAA: Broad Agency Announcement

BBB: Blood-Brain Barrier

CNS: Central Nervous System

FOA: Funding Opportunity Announcement

IC: NIH Institutes and Centers

NOFO: Notice of Funding Opportunity

NOSI: Notice of Special Interest

PI: Principal Investigator

PTSD: Post-Traumatic Stress Disorder

RFI: Request for Information

RFP: Request for Proposal

SBIR: Small Business Innovation Research

SDOH: Social Determinants of Health

STTR: Small Business Technology Transfer

SUD: Substance Use Disorder

TRL: Technology Readiness Level

VCID: Vascular Contributions to Cognitive Impairment and Dementia

Agencies

ARPA-H: Advanced Research Projects Agency for Health

ASPR: Administration for Strategic Preparedness and Response

BARDA: Biomedical Advanced Research and Development Authority

CDC: Centers for Disease Control and Prevention

CDMRP: Congressionally Directed Medical Research Programs

DARPA: Defense Advanced Research Projects Agency

DHA: Defense Health Agency

DoD: Department of Defense

FDA: U.S. Food and Drug Administration

MTEC: Medical Technology Enterprise Consortium

NIH: National Institutes of Health

[Back to Table of Contents](#)

GBG Acronyms

Updated Monthly

January 9, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

NSF: National Science Foundation

PCORI: Patient-Centered Outcomes Research Institute

USAMRDC: U.S. Army Medical Research and Development Command

USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases

USSOCOM: United States Special Operations Command

NIH Institutes and Centers

CC: NIH Clinical Center

CIT: NIH Center for Information Technology

CSR: NIH Center for Scientific Review

FIC: Fogarty International Center

NCATS: National Center for Advancing Translational Sciences

NCCIH: National Center for Complementary and Integrative Health

NCI: National Cancer Institute

NEI: National Eye Institute

NHGRI: National Human Genome Research Institute

NHLBI: National Heart, Lung, and Blood Institute

NIA: National Institute on Aging

NIAAA: National Institute on Alcohol Abuse and Alcoholism

NIAID: National Institute of Allergy and Infectious Diseases

NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases

NIBIB: National Institute of Biomedical Imaging and Bioengineering

NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development

NIDA: National Institute on Drug Abuse

NIDCD: National Institute on Deafness and Other Communication Disorders

NIDCR: National Institute of Dental and Craniofacial Research

NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases

NIEHS: National Institute of Environmental Health Sciences

NIGMS: National Institute of General Medical Sciences

NIMH: National Institute of Mental Health

NIMHD: National Institute on Minority Health and Health Disparities

NINDS: National Institute of Neurological Disorders and Stroke

NINR: National Institute of Nursing Research

NLM: National Library of Medicine

